First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial-Reference-Cited by-同舟云学术

First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial

Published:2021-02 Issue:2 Volume:22 Page:198-211
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Paz-Ares Luis,Ciuleanu Tudor-Eliade,Cobo Manuel,Schenker Michael,Zurawski Bogdan,Menezes Juliana,Richardet Eduardo,Bennouna Jaafar,Felip Enriqueta,Juan-Vidal Oscar,Alexandru Aurelia,Sakai Hiroshi,Lingua Alejo,Salman Pamela,Souquet Pierre-Jean,De Marchi Pedro,Martin Claudio,Pérol Maurice,Scherpereel Arnaud,Lu Shun,John Thomas,Carbone David P,Meadows-Shropshire Stephanie,Agrawal Shruti,Oukessou Abderrahim,Yan Jinchun,Reck Martin

Funder

Bristol-Myers Squibb

Publisher

Elsevier BV

Subject

Oncology

Reference28 articles.

1. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer;Reck;N Engl J Med,2016

2. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer;Gandhi;N Engl J Med,2018

3. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer;Paz-Ares;N Engl J Med,2018

4. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial;Mok;Lancet,2019

5. Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC;Socinski;N Engl J Med,2018

Cited by 906 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Liposomes-enabled cancer chemoimmunotherapy;Biomaterials;2025-02

2. Analysis of immune checkpoint inhibitors for advanced non-small cell lung cancer in patients receiving antacids;Respiratory Investigation;2024-11

3. Five-year outcomes with first-line nivolumab plus ipilimumab with 2 cycles of chemotherapy versus 4 cycles of chemotherapy alone in patients with metastatic non-small cell lung cancer in the randomized CheckMate 9LA trial;European Journal of Cancer;2024-11

4. The Adenosinergic Pathway in Non-Small Cell Lung Cancer;Cancers;2024-09-13

5. Brain Metastases as Inaugural Sign of Non-Small Cell Lung Carcinoma: Case Series and Review of Literature;Cancers;2024-09-08